Pathological Analysis of Diffuse Large B-Cell Lymphoma and Clinical Treatment with Chinese and Western Medicine

机译：弥漫性大B细胞淋巴瘤和中西医临床治疗的病理学分析

获取原文

页面导航

摘要
著录项
相似文献
相关主题

摘要

By exploring the pathogenesis and clinical manifestations of diffuse large B-cell lymphoma, combining Chinese and Western medicine and other treatment for post treatment of diffuse large B-cell lymphoma provides clinical experience.

机译：通过探索弥漫性大B细胞淋巴瘤的发病机制和临床表现，结合中西医药和其他治疗对弥漫性大B细胞淋巴瘤的治疗提供临床经验。

著录项

来源
《International Conference on Management, Education, Information and Control》|2016年|635-1269p|共5页
会议地点
作者
Xianhui Liu; Xiaona Guo; Chunsheng Yan;
展开▼
作者单位

展开▼
会议组织
原文格式 PDF
正文语种
中图分类 TP2-53;
关键词
Diffuse large B cell lymphoma; Pathogenesis; Clinical manifestations; Clinical treatment;

机译：弥漫性大B细胞淋巴瘤;发病机制;临床表现;临床治疗;

相似文献

外文文献
中文文献
专利

1. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. [J] . Snuderl M, Kolman OK, Chen Y American Journal of Surgical Pathology . 2010,第3期

机译：伴有IGH-BCL2和MYC重排的B细胞淋巴瘤是侵袭性肿瘤，其临床和病理特征不同于Burkitt淋巴瘤和弥漫性大B细胞淋巴瘤。
2. T-cell-rich B-cell lymphoma. Analysis of clinical features, response to treatment, survival and comparison with diffuse large B-cell lymphoma. [J] . Tsirigotis P, Economopoulos T, Rontogianni D, Oncology: International Journal of Cancer Research and Treatment . 2001,第4期

机译：富含T细胞的B细胞淋巴瘤。分析临床特征，对治疗的反应，生存率以及与弥漫性大B细胞淋巴瘤的比较。
3. Clinical Significance of BCL2 , C- MYC , and BCL6 Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients [J] . Choo-Yuen Ting, Kian-Meng Chang, Jew-Win Kuan, International Journal of Medical Sciences . 2019,第4期

机译：BCL2，C-MYC和BCL6遗传异常，爱泼斯坦-巴尔病毒感染，CD5蛋白表达，生发中心B细胞/非生发中心B细胞亚型，MYC / BCL2蛋白的共表达和共表达的临床意义弥漫性大B细胞淋巴瘤中MYC / BCL2 / BCL6蛋白的表达：120例患者的临床和病理相关性研究
4. Pathological Analysis of Diffuse Large B-Cell Lymphoma and Clinical Treatment with Chinese and Western Medicine [C] . Xianhui Liu, Xiaona Guo, Chunsheng Yan International Conference on Management, Education, Information and Control . 2016

机译：弥漫性大B细胞淋巴瘤的病理分析及中西医临床治疗
5. FGFR-2 (BEK) Expression in Diffuse Large B-Cell Lymphoma with Clinical Correlation. [D] . Benson, Jenna. 2013

机译：FGFR-2（BEK）在弥漫性大B细胞淋巴瘤中的表达与临床相关性。
6. B-cell Lymphomas with Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms with Clinical and Pathologic Features Distinct from Burkitt Lymphoma and Diffuse Large B-cell Lymphoma [O] . Matija Snuderl, Olga K. Kolman, Yi-Bin Chen, -1

机译：B细胞淋巴瘤具有同时的IGH-BCL2和MYC重排是具有临床和病理特征的侵袭性肿瘤与Burkitt淋巴瘤不同的临床和病理特征并弥漫性大B细胞淋巴瘤
7. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-Cell Non-Hodgkin’s lymphoma1,2 1Expert panel members and authors of the review are: Theresa Hahn, PhD, Roswell Park Cancer Institute, Buffalo, NY; Steven N. Wolff, MD, Vanderbilt University, Nashville, TN, Myron Czuczman, MD, Roswell Park Cancer Institute, Buffalo, NY; Richard I. Fisher, MD, Cardinal Bernardin Cancer Center, Loyola University, Chicago, IL; Hillard M. Lazarus, MD, Comprehensive Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH; Philip L. McCarthy, MD, Roswell Park Cancer Institute, Buffalo, NY; Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE; Lisa Warren, Cure for Lymphoma Foundation, New York, NY; and Richard Watt, MD, United Resource Networks, Minneapolis, MN. 2Reference: Hahn T, Wolff SN, Czuczman M, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin’s lymphoma: an evidence-based review. Biol Blood Marrow Transplant. 2001;7:308–331. [O] . 2003

机译：造血干细胞移植的细胞毒性治疗在治疗弥漫性大细胞B细胞非霍奇金淋巴瘤1,2中的作用1，专家小组成员和评价的作者是：纽约州布法罗罗斯威尔公园癌症研究所的特蕾莎·哈恩博士；田纳西州纳什维尔范德比尔特大学医学博士斯蒂芬·沃尔夫（Steven N. Wolff），纽约州布法罗罗斯维尔公园癌症研究所医学博士迈伦·库兹曼（Myron Czuczman）；理查德·费舍尔（Richard I. Fisher）医学博士，伊利诺伊州芝加哥洛约拉大学贝纳尔丁枢机主教癌症中心；俄亥俄州克利夫兰凯斯西储大学克利夫兰大学医院综合癌症中心医学博士Hillard M. Lazarus；纽约州布法罗罗斯韦尔公园癌症研究所医学博士Philip L.内布拉斯加州奥马哈市内布拉斯加大学医学中心医学博士Julie Vose；丽莎·沃伦（Lisa Warren），纽约州纽约市淋巴瘤基金会的治疗；和明尼苏达州明尼阿波利斯市联合资源网络公司的医学博士Richard Watt。 2参考文献：Hahn T，Wolff SN，Czuczman M等。一项基于证据的综述：造血干细胞移植的细胞毒性治疗在弥漫性大细胞B细胞非霍奇金淋巴瘤治疗中的作用。 Biol骨髓移植。 2001; 7：308-331。

Pathological Analysis of Diffuse Large B-Cell Lymphoma and Clinical Treatment with Chinese and Western Medicine

摘要

著录项

相似文献

相关主题

期刊订阅